{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:49:23Z","timestamp":1793303363456,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semerg.2024.102284","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T09:16:04Z","timestamp":1719306964000},"page":"102284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Revisi\u00f3n narrativa de la terapia inhalatoria en la EPOC"],"prefix":"10.1016","volume":"50","author":[{"given":"M.","family":"Villar Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Calvo Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Aguilar-Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2024.102284_bib0365","unstructured":"2023 Gold Report - Global Initiative for Chronic Obstructive Lung Disease. GOLD [consultado 2 Mar 2023]. Disponible en: https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf"},{"key":"10.1016\/j.semerg.2024.102284_bib0370","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","article-title":"[Spanish COPD Guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD] Actualizaci\u00f3n 2021 de la Gu\u00eda Espa\u00f1ola de la EPOC (GesEPOC). Tratamiento farmacol\u00f3gico de la EPOC estable","volume":"58","author":"Miravitlles","year":"2022","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.semerg.2024.102284_bib0375","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arbres.2021.05.011","article-title":"[Spanish COPD Guidelines (GesEPOC). 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome] Actualizaci\u00f3n 2021 de la gu\u00eda espa\u00f1ola de la EPOC (GesEPOC). Diagn\u00f3stico y tratamiento del s\u00edndrome de agudizaci\u00f3n de la EPOC","volume":"58","author":"Soler-Catalu\u00f1a","year":"2022","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.semerg.2024.102284_bib0380","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: Time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0385","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra1900500","article-title":"Update on clinical aspects of chronic obstructive pulmonary disease","volume":"381","author":"Celli","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0390","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/resp.14041","article-title":"Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact","volume":"26","author":"MacLeod","year":"2021","journal-title":"Respirology."},{"key":"10.1016\/j.semerg.2024.102284_bib0395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arbres.2021.05.011","article-title":"Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome","volume":"58","author":"Soler-Catalu\u00f1a","year":"2022","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.semerg.2024.102284_bib0400","unstructured":"Chronic Obstructive Pulmonary Disease in over 16s: Diagnosis and Management. National Institute for Health and Care Excellence (NICE); 2019 [consultado 2 Mar 2023]. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542426\/"},{"key":"10.1016\/j.semerg.2024.102284_bib0725","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.resinv.2021.08.002","article-title":"Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis","volume":"60","author":"Suzuki","year":"2022","journal-title":"Respir Investig."},{"key":"10.1016\/j.semerg.2024.102284_bib0415","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41533-018-0084-8","article-title":"Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: A post-hoc analysis of randomized trials","volume":"28","author":"D\u2019Urzo","year":"2018","journal-title":"NPJ Prim Care Respir Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0420","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.2147\/COPD.S173472","article-title":"Comparative efficacy of inhaled medications (ICS\/LABA, LAMA, LAMA\/LABA and SAMA) for COPD: A systematic review and network meta-analysis","volume":"13","author":"Aziz","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0425","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12890-020-1152-8","article-title":"Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis","volume":"20","author":"Koarai","year":"2020","journal-title":"BMC Pulm Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0430","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0435","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0440","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.2147\/COPD.S170606","article-title":"LABA\/LAMA fixed-dose combinations in patients with COPD: A systematic review","volume":"13","author":"Rogliani","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0445","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1007\/s12325-022-02234-x","article-title":"Comparative efficacy of umeclidinium\/vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis","volume":"39","author":"Ismaila","year":"2022","journal-title":"Adv Ther."},{"key":"10.1016\/j.semerg.2024.102284_bib0450","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4046\/trd.2020.0109","article-title":"Direct switch from tiotropium to indacaterol\/glycopyrronium in chronic obstructive pulmonary disease patients in Korea","volume":"84","author":"Lee","year":"2021","journal-title":"Tuberc Respir Dis (Seoul)."},{"key":"10.1016\/j.semerg.2024.102284_bib0455","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/resp.13651","article-title":"Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-na\u00efve COPD patients: A pooled analysis","volume":"25","author":"Muro","year":"2020","journal-title":"Respirology."},{"key":"10.1016\/j.semerg.2024.102284_bib0460","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/COPD.S185485","article-title":"Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol\/fluticasone therapy in patients with symptomatic COPD: The POWER study","volume":"14","author":"Kaplan","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0465","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/COPD.S146189","article-title":"The impact of indacaterol\/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study \u2014 the FAVOR study","volume":"13","author":"Kardos","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0470","doi-asserted-by":"crossref","first-page":"101898","DOI":"10.1016\/j.pupt.2020.101898","article-title":"Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients","volume":"61","author":"Benavides-Cordoba","year":"2020","journal-title":"Pulm Pharmacol Ther."},{"key":"10.1016\/j.semerg.2024.102284_bib0475","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620939507","article-title":"Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol\/glycopyrronium versus tiotropium: The RED trial","volume":"14","author":"Beaulieu","year":"2020","journal-title":"Ther Adv Respir Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0480","doi-asserted-by":"crossref","first-page":"2878648","DOI":"10.1155\/2022\/2878648","article-title":"The efficacy and cost-effectiveness of umeclidinium\/vilanterol versus tiotropium in symptomatic patients with chronic obstructive pulmonary disease","volume":"2022","author":"Gong","year":"2022","journal-title":"Can Respir J."},{"key":"10.1016\/j.semerg.2024.102284_bib0485","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12890-021-01612-5","article-title":"Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium\/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: A retrospective cohort study","volume":"21","author":"Slade","year":"2021","journal-title":"BMC Pulm Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0490","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2147\/COPD.S298032","article-title":"Umeclidinium\/vilanterol compared with fluticasone propionate\/salmeterol, budesonide\/formoterol, and tiotropium as initial maintenance therapy in patients with COPD who have high costs and comorbidities","volume":"16","author":"Kalhan","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0495","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s41030-021-00151-y","article-title":"Hospital admission and readmission among US patients receiving umeclidinium\/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease","volume":"7","author":"Slade","year":"2021","journal-title":"Pulm Ther."},{"key":"10.1016\/j.semerg.2024.102284_bib0500","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2147\/COPD.S159103","article-title":"Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD","volume":"13","author":"Chan","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0505","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211066068","article-title":"Quantitative analysis of efficacy and safety of LABA\/LAMA fixed-dose combinations in the treatment of stable COPD","volume":"16","author":"Gong","year":"2022","journal-title":"Ther Adv Respir Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0510","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12931-020-01540-8","article-title":"Comparisons of exacerbations and mortality among LAMA\/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis","volume":"21","author":"Lee","year":"2020","journal-title":"Respir Res."},{"key":"10.1016\/j.semerg.2024.102284_bib0515","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2022.11.027","article-title":"Comparison of clinical outcomes among different fixed-dose combinations of long-acting muscarinic antagonists and long-acting \u03b22-agonists in patients with COPD","volume":"163","author":"Weng","year":"2023","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2024.102284_bib0520","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.3390\/jcm10122649","article-title":"Comparison of effectiveness using different dual bronchodilator agents in chronic obstructive pulmonary disease treatment","volume":"10","author":"Cheng","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0525","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/COPD.S353799","article-title":"Comparing clinical outcomes of tiotropium\/olodaterol, umeclidinium\/vilanterol, and indacaterol\/glycopyrronium fixed-dose combination therapy in patients with chronic obstructive pulmonary disease in Taiwan: A multicenter cohort study","volume":"17","author":"Hsieh","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0530","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.pupt.2021.102076","article-title":"Which LABA\/LAMA should be chosen in COPD patients in real life?","volume":"71","author":"Sposato","year":"2021","journal-title":"Pulm Pharmacol Ther."},{"key":"10.1016\/j.semerg.2024.102284_bib0535","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2147\/COPD.S411437","article-title":"Comparison of rescue medication prescriptions in patients with chronic obstructive pulmonary disease receiving umeclidinium\/vilanterol versus tiotropium bromide\/olodaterol in routine clinical practice in England","volume":"18","author":"Requena","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0540","doi-asserted-by":"crossref","first-page":"2300538","DOI":"10.1183\/13993003.00538-2023","article-title":"Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of chronic obstructive pulmonary disease","volume":"62","author":"Li","year":"2023","journal-title":"Eur Respir J."},{"key":"10.1016\/j.semerg.2024.102284_bib0545","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/COPD.S213520","article-title":"Evaluation of rescue medication use and medication adherence receiving umeclidinium\/vilanterol versus tiotropium bromide\/olodaterol","volume":"14","author":"Moretz","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0550","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12931-018-0916-7","volume":"19","author":"Driessen","year":"2018","journal-title":"Respir Res."},{"key":"10.1016\/j.semerg.2024.102284_bib0555","first-page":"810","article-title":"Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies","volume":"27","author":"Palli","year":"2021","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.semerg.2024.102284_bib0560","doi-asserted-by":"crossref","first-page":"106645","DOI":"10.1016\/j.rmed.2021.106645","article-title":"Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety","volume":"189","author":"Suissa","year":"2021","journal-title":"Respir Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0565","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.4103\/jfmpc.jfmpc_477_19","article-title":"COPD from an everyday primary care point of view","volume":"8","author":"Aguilar-Shea","year":"2019","journal-title":"J Family Med Prim Care."},{"key":"10.1016\/j.semerg.2024.102284_bib0570","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17476348.2019.1665514","article-title":"Comparing a fixed combination of budesonide\/formoterol with other inhaled corticosteroid plus long-acting \u03b2-agonist combinations in patients with chronic obstructive pulmonary disease: A review","volume":"13","author":"Solidoro","year":"2019","journal-title":"Expert Rev Respir Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0575","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1038\/s41598-023-35223-3","article-title":"Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting \u03b2 agonist in patients with COPD","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep."},{"key":"10.1016\/j.semerg.2024.102284_bib0580","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4103\/lungindia.lungindia_136_22","article-title":"Comparative efficacy and safety of glycopyrronium\/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPD","volume":"39","author":"Salvi","year":"2022","journal-title":"Lung India."},{"key":"10.1016\/j.semerg.2024.102284_bib0585","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamainternmed.2023.1245","article-title":"Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers","volume":"183","author":"Feldman","year":"2023","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0590","first-page":"CD012066","article-title":"Long-acting muscarinic antagonist (LAMA) plus long-acting \u03b2-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease","volume":"6","author":"Fukuda","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.semerg.2024.102284_bib0595","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0600","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.chest.2021.05.025","volume":"160","author":"Wang","year":"2021","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2024.102284_bib0605","doi-asserted-by":"crossref","unstructured":"Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, et al. Comparative Effectiveness of Umeclidinium\/Vilanterol versus Inhaled Corticosteroid\/Long-Acting \u03b22-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis. 2023;18:643-659. doi:10.2147\/COPD.S405498","DOI":"10.2147\/COPD.S405498"},{"key":"10.1016\/j.semerg.2024.102284_bib0610","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/COPD.S345263","article-title":"Beyond dual bronchodilation \u2014 Triple therapy, when and why","volume":"17","author":"Cazzola","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0615","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/COPD.S291967","article-title":"Benefit\/risk profile of single-inhaler triple therapy in COPD","volume":"16","author":"Bourbeau","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0620","unstructured":"G\u00f3mez S\u00e1enz JT. El papel de la triple terapia en el tratamiento actual de la EPOC. Respiratorio Atenci\u00f3n Primaria. Abril de 2023, n\u00famero 4. Disponible en: https:\/\/www.livemed.in\/canales\/respiratorio-en-la-red\/respiratorio-atencion-primaria\/numero-4\/pdfs\/relr-n4-el-papel-de-la-triple-terapia-en-el-tratamiento-actual-de-la-epoc.pdf"},{"key":"10.1016\/j.semerg.2024.102284_bib0625","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/jcm11154491","article-title":"Comparing the efficacy and safety profile of triple fixed-dose combinations in COPD: A meta-analysis and IBiS score","volume":"11","author":"Rogliani","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0630","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1159\/000515133","article-title":"Comparisons of efficacy and safety between triple (inhaled corticosteroid\/long-acting muscarinic antagonist\/long-acting \u03b2-agonist) therapies in chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis","volume":"100","author":"Lee","year":"2021","journal-title":"Respiration."},{"key":"10.1016\/j.semerg.2024.102284_bib0635","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4187\/respcare.10188","article-title":"Therapeutic response to single-inhaler triple therapies in moderate-to-severe COPD","volume":"68","author":"Ohtsuka","year":"2023","journal-title":"Respir Care."},{"key":"10.1016\/j.semerg.2024.102284_bib0640","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2024.102284_bib0645","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41533-021-00241-z","article-title":"Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy versus tiotropium monotherapy in patients with COPD","volume":"31","author":"Bansal","year":"2021","journal-title":"NPJ Prim Care Respir Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0650","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","article-title":"Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: Lung function and health status results from two replicate randomized controlled trials","volume":"21","author":"Ferguson","year":"2020","journal-title":"Respir Res."},{"key":"10.1016\/j.semerg.2024.102284_bib0655","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2024.102284_bib0660","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0665","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0670","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0675","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/COPD.S386962","article-title":"Healthcare resource utilization, cost and clinical outcomes in patients diagnosed with COPD initiating tiotropium bromide\/olodaterol versus fluticasone furoate\/umeclidinium\/vilanterol based on exacerbation history","volume":"18","author":"Sethi","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0680","first-page":"791","article-title":"Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide\/olodaterol or fluticasone furoate\/umeclidinium\/vilanterol","volume":"29","author":"Sethi","year":"2023","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.semerg.2024.102284_bib0685","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.chest.2019.11.007","article-title":"Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort study in real-world clinical practice","volume":"157","author":"Suissa","year":"2020","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2024.102284_bib0690","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/COPD.S381138","article-title":"Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study","volume":"17","author":"De Nigris","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0695","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.2147\/COPD.S384591","article-title":"Cost-effectiveness analysis of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate versus dual therapy in patients with chronic obstructive pulmonary disease in Spain","volume":"17","author":"Trigueros","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.semerg.2024.102284_bib0700","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1007\/s12325-023-02524-y","article-title":"EVELUT\u00ae: A real-world, observational study assessing dyspnoea and symptom burden in COPD patients switched from LABA\/ICS to LAMA\/LABA or LAMA\/LABA\/ICS","volume":"40","author":"Buhl","year":"2023","journal-title":"Adv Ther."},{"key":"10.1016\/j.semerg.2024.102284_bib0705","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary Disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0710","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2024.102284_bib0715","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.semerg.2024.102284_bib0720","doi-asserted-by":"crossref","first-page":"00119","DOI":"10.1183\/23120541.00119-2017","article-title":"Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses","volume":"4","author":"Halpin","year":"2018","journal-title":"ERJ Open Res."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359324000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359324000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:53:28Z","timestamp":1727679208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359324000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1138359324000947"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2024.102284","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisi\u00f3n narrativa de la terapia inhalatoria en la EPOC","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2024.102284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102284"}}